视网膜静脉阻塞性黄斑水肿的治疗  

Treatment of macular edema to retinal vein occlusion

作　　者：卢颖毅[1] 戴虹[1] LU Ying-yi;DAI Hong(Department of Ophthalmology,Beijing Hospital,National Center of Gerontology,Beijing 100730, China)

机构地区：[1]北京医院眼科国家老年医学中心

出　　处：《临床药物治疗杂志》2019年第6期35-39,共5页Clinical Medication Journal

摘　　要：视网膜静脉阻塞(retinal vein occlusion,RVO)是一种老年人群中常见的视网膜血管性疾病,黄斑水肿是导致患者视力损伤的主要并发症。目前RVO黄斑水肿的主要治疗方式为玻璃体腔内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物或者植入地塞米松玻璃体内植入剂,二者均能显著改善患者视力,减轻黄斑水肿。对于抗VEGF药物或其他治疗反应不佳的患者,地塞米松缓释植入剂同样有效。RVO黄斑水肿的临床预后与治疗时机有关,早期治疗的患者视力获益更多。Retinal vein occlusion(RVO)is a retinal vascular disease frequently occurred in the elder population,and macular edema is the major complication associated with severe vision impairment.At present,the main treatments of RVO macular edema are intravitreal anti-VEGF agents or intravitreal implantation of dexamethasone,both of them can significantly improve visual acuity and alleviate macular edema.Additionally,dexamethasone sustained-release implants can be effectively used among patients with poor response to intravitreal anti-VEGF agents or other treatments.The clinical prognosis of RVO macular edema is related to the treatment timing,and patients with early treatment could benefit more from visual acuity.

关 键 词：视网膜静脉阻塞 黄斑水肿 地塞米松 血管内皮生长因子 

分 类 号：R774[医药卫生—眼科]